EAGLE PHARMACEUTICALS INC innovation strategy

Patent filings in countries

#	Country	Total Patents
#1	United States	42
#2	WIPO (World Intellectual Property Organization)	16
#3	EPO (European Patent Office)	15
#4	Canada	13
#5	China	12
#6	Japan	8
#7	Australia	5
#8	Republic of Korea	5
#9	Brazil	4
#10	Israel	4
#11	Mexico	3
#12	Colombia	2
#13	Hungary	2
#14	Serbia	2
#15	Singapore	2

#	Industry
#1	Pharmaceuticals
#2	Organic fine chemistry

#	Technology
#1	Medical preparations
#2	Therapeutic chemical compounds
#3	Special acyclic compounds
#4	Heterocyclic compounds

Publication	Filing date	Title
JP2021001225A	2020-10-05	Pemetrexed formulations
WO2020112932A1	2019-11-27	Use of dantrolene and dantrolene prodrugs to treat radiation exposure
CA3101093A1	2019-05-21	Dantrolene formulations and methods of their use
US2020360284A1	2018-11-08	Fulvestrant formulations and methods of their use
KR20200085809A	2018-11-08	Fulvestrant formulation and method of use thereof
WO2019079721A1	2018-10-19	Dantrolene prodrugs and methods of their use
EP3678659A1	2018-09-05	Methods of using dantrolene to treat nerve agent exposure
AU2017261321A1	2017-05-05	Fulvestrant formulations and methods of their use
US2017239250A1	2016-02-19	Pemetrexed formulations
CA3014755A1	2016-02-19	Pemetrexed formulations
WO2015175668A1	2015-05-13	Aqueous buffer-free bivalirudin compositions
EP3533447A1	2013-03-15	Bendamustine liquid compositions for use in method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
US2013253025A1	2013-03-15	Formulations of bendamustine
US2013210879A1	2013-02-14	Formulations of bendamustine
WO2012015810A2	2011-07-26	Pharmaceutical compositions containing pemetrexed having extended storage stability
HUE031208T2	2011-01-28	Formulations of bendamustine
WO2011035108A1	2010-09-17	Formulations of daptomycin
CA2774094A1	2010-09-17	Formulations of daptomycin
WO2011014541A1	2010-07-28	Stable formulations of azacitidine
CA2715832A1	2009-02-27	Topotecan ready to use solutions